Eli Lilly's Weight-Loss Drug Costs Less Than Wegovy. Here's Why.
Eli Lilly says the list price of its obesity drug, Zepbound, is roughly 20% lower than the list price of Novo Nordisk's Wegovy.
Source: marketwatch.com
📰 David Ricks News
Page 20 - David Ricks News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from David Ricks. Real-time updates on events, politics, business and more.
Eli Lilly and Company (NYSE:LLY) Q3 2023 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY) Q3 2023 Earnings Call Transcript November 2, 2023 Eli Lilly and Company beats earnings expectations. Reported EPS is $0.1, expectations were $-0.11. Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2023 Earnings Call. At this time all participants are in a listen-only mode […]
Source: yahoo.com
Eli Lilly and Company (NYSE:LLY) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2023 Earnings Call. At this time all participants are in a listen-only mode [Operator Instructions].
Source: insidermonkey.com
Eli Lilly Cuts Its Profits For The Full Year Despite Mounjaro's Strength
(CTN News) - Despite strong demand for its diabetes drug Mounjaro, Eli Lilly on Thursday slashed its profit guidance for the full...........
Source: chiangraitimes.com
Novo Nordisk, Eli Lilly sales soar amid weight-loss craze
Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.
Source: fortune.com
Lilly posts 3Q loss of $57M, cuts full-year profit guidance – Indianapolis Business Journal
Excluding nonrecurring items, the Indianapolis-based drugmaker posted adjusted earnings of 10 cents a share, beating Zacks consensus estimate of a loss of 11 cents a share.
Source: ibj.com
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
The remarks suggest that Eli Lilly’s initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment soars.
Source: nbcsandiego.com
Eli Lilly diabetes drug Mounjaro supply improves in U.S.
The remarks suggest that Eli Lilly's initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment soars.
Source: cnbc.com